The National Institutes of Health said on Friday it has started a
clinical study to test a combination of Gilead Sciences Inc’s antiviral
drug remdesivir and anti-inflammatory drug baricitinib in COVID-19
patients.
The trial is currently enrolling adults hospitalized with COVID-19 in
the United States and is expected to study the treatment combination in
more than 1,000 participants. (bit.ly/2YM0tfp)
Baricitinib, which is marketed under brand name Olumiant by Eli Lilly
and Co, was being tested as a potential treatment for hospitalized
patients diagnosed with COVID-19.
https://www.reuters.com/article/us-health-coronavirus-remdesivir/nih-begins-study-of-remdesivir-with-anti-inflammatory-drug-to-treat-covid-19-idUSKBN22K2M7
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.